Insulin Resistance: Comprehensive Management Strategies

Insulin resistance (IR) underlies type 2 diabetes, metabolic syndrome, PCOS, and cardiovascular disease. Management targets improved insulin sensitivity through lifestyle, pharmacotherapy, and treatment of underlying drivers.

Diagnostic Criteria

  • HOMA-IR: (Fasting insulin × Fasting glucose)/405; >2.5 suggests IR
  • Triglyceride/HDL ratio: >3.5 correlates with IR
  • Clinical markers: Acanthosis nigricans, skin tags, central obesity, hypertension, dyslipidemia
  • OGTT with insulin: Gold standard for research

Lifestyle Interventions (Cornerstone)

Weight Management

  • 5-10% weight loss → 30-60% improvement in insulin sensitivity
  • Target: 0.5-1 kg/week via 500-750 kcal deficit
  • Visceral fat reduction more important than total weight

Nutrition

  • Pattern: Mediterranean, DASH, low-glycemic load, moderate carb (40-45%)
  • Prioritize: Fiber (≥30g), omega-3s, polyphenols, magnesium, chromium
  • Limit: Refined carbs, added sugars, saturated/trans fats, alcohol
  • Timing: Time-restricted eating (10-12h window) may improve circadian insulin sensitivity

Physical Activity

  • Aerobic: 150-300 min/week moderate (brisk walk, cycle, swim)
  • Resistance: 2-3×/week all major muscle groups (muscle = major glucose disposal site)
  • HIIT: Time-efficient, potent insulin sensitizer
  • Postprandial walks: 10-15 min after meals blunts glucose spikes
  • Reduce sedentary time: Stand/walk every 30 min

Sleep & Stress

  • 7-9 hours; treat sleep apnea (major IR driver)
  • Stress → cortisol → hepatic gluconeogenesis, visceral adiposity
  • Mindfulness, CBT, nature exposure reduce cortisol

Smoking Cessation

Smoking increases IR via inflammation, oxidative stress, sympathetic activation. Quitting improves sensitivity within weeks.

Pharmacotherapy

Emerging/Adjunctive

  • Berberine: AMPK activation; modest evidence, drug interactions
  • Inositol (myo + D-chiro): Especially for PCOS-related IR
  • Magnesium: Corrects deficiency common in IR
  • Vitamin D: Repletion if deficient (<30 ng/mL)

Monitoring

  • HbA1c q3-6mo (target <5.7% prediabetes, <7% T2DM individualized)
  • Fasting glucose, lipid panel, LFTs, renal function
  • Weight, waist circumference, BP
  • Assess adherence, barriers quarterly

Special Populations

  • PCOS: Metformin + lifestyle first-line; GLP-1 RA for obesity
  • Pediatric: Lifestyle only; metformin if persistent >10yo with comorbidities
  • Pregnancy: Insulin only; metformin sometimes continued for PCOS

Diabetes - Related Articles

Health Sciences © https://www.222health.com

AgentMechanismIndicationKey Considerations
Metformin↓ Hepatic gluconeogenesis, ↑ AMPK, ↑ GLUT4First-line for IR, prediabetes, T2DM, PCOSGI side effects; B12 monitoring; contraindicated eGFR<30
TZDs (pioglitazone)PPAR-γ agonist → ↑ adiponectin, ↑ insulin sensitivityAdjunct; NASH benefitWeight gain, edema, fracture risk, bladder cancer concern
SGLT2 inhibitors↑ Glucosuria → ↓ glucotoxicity, ↑ insulin sensitivityT2DM, HF, CKDGenital mycotic infections, euglycemic DKA risk
GLP-1 RAs↑ Insulin, ↓ glucagon, ↓ appetite, ↓ gastric emptyingT2DM, obesity, CV risk reductionNausea, cost; semaglutide/liraglutide approved for obesity
DPP-4 inhibitors↑ Endogenous GLP-1T2DMWeight neutral, modest efficacy